CD274 and neoplasm: Biomarkers including PD-L1 expression in the tumor cells4, the presence of tumor-infiltrating lymphocytes at the invasive tumor margin5, and the nonsynonymous mutation burden frequency in the tumor cells6 have been shown to predict the effect of nivolumab.